

January 24, 2020

IMMUNOLOGY

Autoimmune Testing Changes

Date effective: February 3, 2020**Background Information:**

Autoimmune testing is performed at the Immunology Laboratory at St. Boniface Hospital. Reagents for Indirect Immunofluorescence Assay (IFA) and Enzyme-Linked Immunosorbent Assay (ELISA) have, in the past, been supplied by multiple vendors. To improve efficiency and standardization, these tests will now be provided by a single vendor.

Change in Test Procedure:

The following changes will come into effect **February 3, 2020**:

1. **NEW Test Code: LDP:** Anti-Mitochondrial (AMA), Anti-Smooth Muscle (SMA), and Anti-Liver/Kidney Microsomal (LKM) are no longer orderable individually but are included in a new liver disease panel along with anti-nuclear antibody(HEP2).
2. **NEW Test Code: IBD:** Anti-Saccharomyces Cerevisiae (IgG/IgA) is no longer orderable as a standalone test but is included in a new Inflammatory Bowel Disease panel along with Cytoplasmic Neutrophilic Ab (ANCA).
3. ANCA is still orderable for diagnosis of Vasculitis and will include reflex testing for MPO and/or PR3 as appropriate.
4. **NEW Test Code: ABD:** Bullous Dermatoses testing for Pemphigus/Pemphigoid will now include Desmogleins (Dsg1/Dsg3) or BP180/BP230, as appropriate, to help further classify the disease.
5. Reference range changes for most tests. Most notably, ANA HEP2 which will change from <1:40 to <1:80 titre.
6. A new Immunology Autoimmune Laboratory Requisition will accompany the above changes.

References/Resources:

Refer to the [Laboratory Information Manual](#) for further information on each test, including clinical details, sample requirements, reference ranges, and turnaround times. These changes will not be viewable until the February 3, 2020 effective date.

- Immunology Autoimmune Laboratory Requisition [R250-10-85]
- Cytoplasmic Neutrophilic Antibodies [ANCA]
- Antinuclear Antibodies [HEP2]
- Liver Disease Profile [LDP]
- Acetylcholine Receptor [ACHR]
- Striated Muscle Antibody [STR]
- Inflammatory Bowel Disease [IBD]
- Bullous Dermatoses [ABD]
- Parietal Cell Antibody [PCA]
- Endomysial Antibody (IgA) [AEMA]

Patient Impact:

- Decreased turnaround time for most tests.

Contact Information:

- Dr. Ping Sun, Hematopathologist, Medical Director Hematology & Immunology, Shared Health Manitoba, (phone: 204-787-4682) psun@sharedhealthmb.ca
- Jason Warren, Immunology Technical Manager, Shared Health Manitoba, (phone: 204-787-3407) jwarren3@sharedhealthmb.ca